Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest Expenses (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Interest Expenses for 7 consecutive years, with $98000.0 as the latest value for Q2 2017.

  • For Q2 2017, Interest Expenses fell 81.54% year-over-year to $98000.0; the TTM value through Mar 2018 reached $98000.0, down 94.07%, while the annual FY2016 figure was $2.0 million, 31.23% down from the prior year.
  • Interest Expenses hit $98000.0 in Q2 2017 for Corcept Therapeutics, down from $225000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.2 million in Q3 2013 and bottomed at $98000.0 in Q2 2017.
  • Average Interest Expenses over 5 years is $753235.3, with a median of $770000.0 recorded in 2015.
  • Year-over-year, Interest Expenses soared 22720.0% in 2013 and then tumbled 81.54% in 2017.
  • Corcept Therapeutics' Interest Expenses stood at $1.1 million in 2013, then dropped by 25.23% to $818000.0 in 2014, then dropped by 15.4% to $692000.0 in 2015, then crashed by 40.75% to $410000.0 in 2016, then tumbled by 76.1% to $98000.0 in 2017.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $98000.0, $225000.0, and $410000.0 for Q2 2017, Q1 2017, and Q4 2016 respectively.